Profile: Danaher Corp (DHR)
16 Mar 2018
Danaher Corporation (Danaher), incorporated on October 3, 1986, designs, manufactures and markets professional, medical, industrial and commercial products and services. As of December 31, 2016, the Company's research and development, manufacturing, sales, distribution, service and administrative facilities were located in over 60 countries. Danaher operates through four segments: Life Sciences; Diagnostics; Dental, and Environmental & Applied Solutions.
The Company's Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Life Sciences segment, through its Pall Corporation (Pall) business, is also a provider of filtration, separation and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics and general industrial sectors. The Life Sciences segment consists of the businesses, including microscopy, mass spectrometry and filtration. The life sciences business markets its products under the BECKMAN COULTER, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. Its manufacturing facilities are located in Europe, Australia, Asia and North America.
The microscopy business is engaged in providing professional microscopes designed to manipulate, preserve and capture images of and enhance the user's visualization and analysis of microscopic structures. The Company's microscopy products include laser scanning (confocal) microscopes; compound microscopes and related equipment; surgical and other stereo microscopes, and specimen preparation products for electron microscopy. These products are used in research and pathology laboratories, academic settings and surgical theaters. Its mass spectrometry business is engaged in providing high-end mass spectrometers, as well as related consumable chromatography columns and sample preparation extraction products. The mass spectrometers utilize various combinations of quadrupole, time-of-flight and ion trap technologies, and are used in conjunction with a liquid chromatography instrument. The business' mass spectrometer systems and related products are used in various applications, such as drug discovery and clinical development of therapeutics, as well as in basic research, clinical testing, food and beverage quality testing and environmental testing.
The mass spectrometry products are used by molecular biologists, bioanalytical chemists, toxicologists, and forensic scientists, as well as quality assurance and quality control technicians. The mass spectrometry business also provides bioanalytical measurement systems, including microplate readers, automated cellular screening products and associated reagents, and imaging software. The mass spectrometry business also offers workflow instruments and consumables that help researchers analyze genomic, protein and cellular information. Key product areas include sample preparation equipment, such as centrifugation and capillary electrophoresis instrumentation and consumables; liquid handling automation instruments and associated consumables; flow cytometry instrumentation and associated antibodies and reagents, and particle characterization instrumentation. Pall's materials and technologies can be applied in various ways to solve fluid separation challenges, and are sold across an array of applications in two primary business groups: life sciences and industrial.
Pall's life sciences technologies facilitate the process of drug discovery, development, regulatory validation and production and are sold to biopharmaceutical, food and beverage and medical customers. In the biopharmaceutical area, the business sells a line of filtration and purification technologies, single use bioreactors and associated accessories, hardware and engineered systems primarily to pharmaceutical and biopharmaceutical companies for use in the development and commercialization of chemically synthesized and biologically derived drugs, plasma and vaccines. Pall's industrial technologies enhance manufacturing processes and prolong equipment life in applications, such as semiconductor equipment, airplanes, oil refineries, power generation turbines, petrochemical plants, municipal water plants and mobile mining equipment.
The Company's Diagnostics segment offers analytical instruments, reagents, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The diagnostics business consists of the clinical laboratory (or clinical lab), molecular, critical care and anatomical pathology diagnostics businesses. The clinical lab business is a manufacturer and marketer of biomedical testing instruments, systems and related consumables that are used to evaluate and analyze samples made up of body fluids, cells and other substances. The clinical lab business offers products, including chemistry systems, immunoassay systems, microbiology systems, automation systems, and hematology and flow cytometry products for cellular analysis. Chemistry systems use electrochemical detection and chemical reactions with patient samples to detect and quantify substances of diagnostic interest in blood, urine and other body fluids. Immunoassay systems also detect and quantify biochemicals of diagnostic interest (such as proteins and hormones) in body fluids, particularly in circumstances where specialized diagnosis is required.
The business' hematology systems use principles of physics, optics, electronics and chemistry to separate cells of diagnostic interest and then quantify and characterize them, allowing clinicians to study formed elements in blood (such as red and white blood cells and platelets). The business' flow cytometry products sort, identify, categorize and characterize multiple types of cells in suspension, allowing clinicians to determine cell types and characteristics and analyze specific cell populations based on molecular differences, which is critical to human immunodeficiency virus (HIV) and leukemia diagnosis and monitoring. Its microbiology systems are used for the identification of bacteria and antibiotic susceptibility testing (ID/AST) from human clinical samples, to detect and quantify bacteria related to microbial infections in urine, blood, and other body fluids, and to detect infections, such as urinary tract infections, pneumonia and wound infections. Automation systems reduce manual operation and associated cost and errors from the pre-analytical through post-analytical stages, including sample barcoding/information tracking, centrifugation, aliquotting, storage and conveyance.
The molecular diagnostics business is engaged in the manufacturing and marketing of biomedical testing instruments, systems and related consumables that enable deoxyribonucleic acid (DNA)-based testing for organisms and genetic-based diseases in both clinical and non-clinical markets. The business' products integrate and automate the time-intensive steps associated with DNA-based testing (including sample preparation and DNA amplification and detection) to allow the testing to be performed in both laboratory and non-laboratory environments. The business' systems test for healthcare-associated infections (such as methicillin-resistant staphylococcus aureus (MRSA) and Clostridium Difficile (C diff.)), respiratory disease (such as tuberculosis and influenza), sexual health (such as gonorrhea and chlamydia) and virology (such as HIV and hepatitis). The critical care diagnostics business is engaged providing instruments, software and related consumables and services that are used in both laboratory and point-of-care environments to measure parameters, including blood gases, electrolytes, metabolites and cardiac markers, as well as for anemia and glucose testing.
The anatomical pathology diagnostics business is engaged in the anatomical pathology industry, offering a suite of instrumentation and related consumables used across the entire workflow of a pathology laboratory. The anatomical pathology diagnostics products include minimally invasive, vacuum-assisted breast biopsy collection instruments; tissue embedding, processing and slicing (microtomes) instruments and related reagents and consumables; chemical and immuno-staining instruments, reagents, antibodies and consumables; slide coverslipping and slide/cassette marking instruments, and imaging instrumentation, including slide scanners, microscopes, cameras and software solutions to store, share and analyze pathology images digitally.
The Company's Dental segment provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The Company provides a range of dental consumables, equipment and services. The dental businesses develop, manufacture and market the dental consumables and dental equipment, including implant systems, dental prosthetics and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments including rotary burrs, impression materials, bonding agents and cements; infection prevention products; digital imaging systems and software and other visualization and magnification systems; air and electric powered handpieces and associated consumables, and treatment units. The dental products are marketed primarily under the DEXIS, iCAT, IMPLANT DIRECT, INSTRUMENTARIUM DENTAL, KAVO, KERR, NOBEL BIOCARE, ORMCO, PELTON & CRANE, PENTRON, SOREDEX, SYBRON ENDO and TOTAL CARE brands. Its manufacturing facilities are located in Europe, North America, South America and Asia.
Environmental & Applied Solutions
The Company's Environmental & Applied Solutions segment products and services help protect resources and keep global food and water supplies safe. The Company's Environmental & Applied Solutions segment consists of various lines of business, including water quality and product identification. The Company's water quality business provides instrumentation, services and disinfection systems to help analyze, treat and manage the quality of ultra-pure, potable, waste, ground, source and ocean water in residential, commercial, industrial and natural resource applications. The water quality business designs, manufactures and markets a range of analytical instruments, software and related consumables and services; ultraviolet disinfection systems, and industrial water treatment solutions. The water quality business provides products under a range of brands, including CHEMTREAT, HACH, MCCROMETER and TROJAN TECHNOLOGIES. Its manufacturing facilities are located in North America, Europe, Asia and Latin America.
The Company's product identification business provides equipment, consumables, software and services for various printing, marking, coding, traceability, packaging, design and color management applications on consumer, pharmaceutical and industrial products. The product identification business provides color solutions through measurement systems, software, color standards and related services. It provides software for packaging, label and display artwork creation, structural design, and pre-press applications workflow automation, digital asset management, quality assurance and online collaboration. The product identification business provides a range of equipment and solutions used to give products identities by printing date, lot and bar codes and other information on primary and secondary packaging. The product identification products are primarily marketed under the ESKO, FOBA, LAETUS, LINX, PANTONE, VIDEOJET and X-RITE brands. Its manufacturing facilities are located in North America, Europe, South America and Asia.
2200 Pennsylvania Ave NW Ste 800
WASHINGTON DC 20037-1731
Company Web Links
- BRIEF-Danaher To Acquire Integrated DNA Technologies
- BRIEF-Danaher Says Expects Q1 2018 Adjusted Diluted Net EPS To Be Above High-End Of Co's Previously Communicated Guidance Range
- BRIEF-Danaher Reports Q4 EPS Of $1.21
- BRIEF-Danaher Sees FY 2018 Adjusted Earnings Per Share $4.25 To $4.35
- BRIEF-Danaher Announces Leadership Appointment